Amgen partnering with Japanese company to develop biosimilars
Thousand Oaks-based biotech giant Amgen said July 13 it will partner with a Japanese company to develop and commercialize biosimilars in Japan. Under the partnership, Amgen will develop and manufacture biosimilars while Daiichi Sankyo will obtain marketing approval, distribution and commercialization rights in Japan for the products. The deal also includes several late-stage development drugs. Read More →
Read More →FDA panel recommends Amgen biosimilar drug for approval
A Food and Drug Administration panel recommended an Amgen biosimilar drug for approval July 12, just days after it said the biosimilar performed like a drug it mimicked. ABP 501, made by Thousand Oaks biotech giant Amgen, replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and Read More →
Read More →FDA OKs wearable injector for Amgen’s Repatha cholesterol drug
The U.S. Food and Drug Administration approved a new type of injector for Amgen’s cholesterol reducing drug Repatha on July 11. The FDA approved a wearable injector, called the “Pushtronex” system, that sticks to patients’ bodies and delivers a dose of the drug monthly under the skin. Patients can perform moderate physical activities like walking Read More →
Read More →FDA finds Amgen biosimilar replicates effects of Humira
The Food and Drug Administration said a new Amgen biosimilar replicates the effects of a competitor’s blockbuster drug July 8. ABP 501 replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and colon inflammation. The drug, made by Chicago-based competitor AbbVie, typically costs $20,000 per year for Read More →
Read More →Europeans OK Amgen’s Kyprolis for multiple myeloma treatment
European regulators approved Amgen’s potential blockbuster drug Kyprolis on July 4 as a treatment for multiple myeloma. The European Commission approved a treatment of Kyprolis and dexamethasone in patients who’ve received at least one previous multiple myeloma treatment. In November, the commission approved a Kyprolis treatment using lenalidomide and dexamethasone for patients who’ve received at Read More →
Read More →Dubroff: Appeal of populism falls short of reality
“You say you want a revolution Well, you know, we all want to change the world” — John Lennon My verdict on the so-called “Brexit” vote is that in a globalized world dominated by central bankers, it is far more profitable to sing about a revolution than to actually foment one. Less than a week Read More →
Read More →Dubroff: Brexit impacts will be felt in Tri-Counties
Brexit has become a crisis with a long tail and more than a twinge of buyers’ remorse. As Sung Won Sohn of CSU Channel Islands pointed out in comments to the Business Times, the narrow EU exit vote victory was a boost for populism in the U.S. and elsewhere. It could lead to the disintegration Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
